Advertisements

Immune Pharmaceuticals Inc. (IMNP) Stock Quote

Detailed Quote for Immune Pharmaceuticals Inc. (IMNP)
$ 2.47   -0.0199 (-0.80%) Volume: 107.1k 4:00 PM EDT Jul 20, 2017
After Hours:  $ 2.39   -0.08 (-3.24%) Volume: 15.71k 6:53 PM EDT Jul 20, 2017
Today 5d 1m 3m 1y more
Last Price
2.47
Change $
0.0199
Change %
0.80%
Tick
  
Bid
2.16
Bid Size
100
Ask
3.75
Ask Size
4,000
Open
2.50
High
2.50
Low
2.419
Prev Close
2.4899
Last Trade
07/20/17
Volume
107.1k
52 Wk Hi
10.1999998
52 Wk Low
2.10999989
Market Cap
24.61m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
9,964,301
EPS (TTM)
-6.61000013
PE Ratio
N/A
Exchange
NCM
News and Media for Immune Pharmaceuticals Inc. (IMNP)
Sector News | Topic News
News for Immune Pharmaceuticals Inc. (IMNP)
Wed, Jul 19, 2017
10:37 AM Immune Pharma considering pro rata share distribution to shareholders to spin out Cytovia - SeekingAlpha
9:32 AM Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company - Business Wire
Thu, Jul 13, 2017
7:30 AM IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene\u00AE in Acute Myeloid Leukemia (AML) and Other Hematological Cancers with Mutated\u00A0NPM1 - Business Wire
Tue, Jul 11, 2017
1:45 PM Cytovia Inc, Immune Pharmaceuticals' Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene\u00AE in Latin America - Business Wire
Wed, Jul 05, 2017
9:24 AM Premarket Gainers as of 9:05 am - SeekingAlpha
8:30 AM IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene\u00AE in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology Journal - PR Newswire
Thu, Jun 29, 2017
1:00 PM NetworkNewsBreaks - Top 10 Mid-day Percentage Gainers on June 29, 2017 - NetworkNewsWire
9:17 AM Premarket Gainers as of 9:05 am - SeekingAlpha
8:30 AM Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of Ceplene\u00AE in Latin America - PR Newswire
Tue, Jun 20, 2017
9:14 AM Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene\u00AE/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML) - PR Newswire
Mon, Jun 19, 2017
8:30 AM Immune Receives NASDAQ Compliance Letter - PR Newswire
Thu, Jun 15, 2017
9:28 AM Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene - PR Newswire
Fri, May 26, 2017
8:30 AM Immune Receives Nasdaq Letters - PR Newswire
Thu, May 04, 2017
10:50 AM Immune Pharma sinks on private placement - SeekingAlpha
9:00 AM Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million - PR Newswire
Fri, Apr 28, 2017
6:16 PM Immune Pharmaceuticals Inc. (IMNP) Pressures Healthcare Sector with a Slide of 2.3% on April 27 - FP News
Tue, Apr 25, 2017
9:44 AM Immune Pharmaceuticals Inc. (IMNP) Pressures Healthcare Sector with a Slide of 20.96% on April 24 - FP News
9:42 AM Health Care Sector Feels Weight of 4.53% Slide in Early Trading of Immune Pharmaceuticals Inc. (IMNP) on April 24 - FP News
Mon, Apr 24, 2017
9:15 AM Immune Pharma restructures ahead of possible spin-off of Cytovia unit; shares down 9% premarket - SeekingAlpha
8:30 AM Immune Pharmaceuticals Announces Corporate Restructuring - PR Newswire
More News for IMNP >>

Tags for Immune Pharmaceuticals Inc.

Research stocks or mutual funds related to Immune Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to IMNP. The keywords below have been associated to IMNP by either user submission or electronic means.